Safety of Atazanavir Boosted with Ritonavir in Pediatric HIV

Phase 4, open-label trial of atazanavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants Who Died and With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Grade 2-4 Related AEs, Grade 3-4 AEs, and CDC Class C AIDS Events at 42 months and Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormal, Grades 1-4 at 42 months. Started Nov 2012; status: completed.